Zujiang Yu

5.4k total citations · 2 hit papers
101 papers, 3.0k citations indexed

About

Zujiang Yu is a scholar working on Molecular Biology, Epidemiology and Hepatology. According to data from OpenAlex, Zujiang Yu has authored 101 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 31 papers in Epidemiology and 23 papers in Hepatology. Recurrent topics in Zujiang Yu's work include Liver Disease Diagnosis and Treatment (20 papers), RNA modifications and cancer (16 papers) and Cancer-related molecular mechanisms research (16 papers). Zujiang Yu is often cited by papers focused on Liver Disease Diagnosis and Treatment (20 papers), RNA modifications and cancer (16 papers) and Cancer-related molecular mechanisms research (16 papers). Zujiang Yu collaborates with scholars based in China, United States and France. Zujiang Yu's co-authors include Zhigang Ren, Ang Li, Guangying Cui, Ranran Sun, Quancheng Kan, Benchen Rao, Quancheng Kan, Liangjie Hong, Yubing Zhou and Shichao Sun and has published in prestigious journals such as The Lancet, Advanced Materials and Journal of Clinical Oncology.

In The Last Decade

Zujiang Yu

95 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma

2018 543 citations Zhigang Ren, Ang Li et al. Gut profile →
A Metal–Polyphenol‐Coordinated Nanomedicine for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy

2019 387 citations Zhigang Ren, Ranran Sun et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zujiang Yu China	26	1.7k	628	573	420	408	101	3.0k
Guangying Cui China	33	2.1k 1.2×	729 1.2×	576 1.0×	588 1.4×	381 0.9×	82	3.4k
Yufeng Yuan China	32	1.9k 1.1×	1.3k 2.0×	346 0.6×	436 1.0×	515 1.3×	114	3.3k
Yang Xia China	38	2.1k 1.2×	952 1.5×	455 0.8×	841 2.0×	270 0.7×	195	4.5k
Lang Bai China	28	831 0.5×	388 0.6×	593 1.0×	306 0.7×	286 0.7×	151	2.8k
Qiuju Han China	31	1.6k 0.9×	608 1.0×	733 1.3×	525 1.3×	175 0.4×	95	3.1k
Lingli Chen China	32	1.5k 0.9×	420 0.7×	369 0.6×	772 1.8×	1.1k 2.8×	103	4.0k
Norihiro Kokudo Japan	27	901 0.5×	318 0.5×	317 0.6×	485 1.2×	219 0.5×	58	2.2k
Rong Liang China	28	1.1k 0.7×	621 1.0×	229 0.4×	475 1.1×	171 0.4×	127	2.6k
Xiaofeng Lu China	32	1.4k 0.8×	457 0.7×	208 0.4×	430 1.0×	385 0.9×	165	3.3k

Countries citing papers authored by Zujiang Yu

Since Specialization

Citations

This map shows the geographic impact of Zujiang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zujiang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zujiang Yu more than expected).

Fields of papers citing papers by Zujiang Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zujiang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zujiang Yu. The network helps show where Zujiang Yu may publish in the future.

Co-authorship network of co-authors of Zujiang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Zujiang Yu. A scholar is included among the top collaborators of Zujiang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zujiang Yu. Zujiang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Yongjian, Shixi Zhang, Donghua Zhang, et al.. (2025). A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes. Frontiers in Endocrinology. 16. 1467303–1467303.

Li, Yaoguang, Peng Han, Jun Lei, et al.. (2025). Performance and hypothetical clinical impact of an mNGS-based machine learning model for antimicrobial susceptibility prediction of five ESKAPEE bacteria. Microbiology Spectrum. 13(6). e0259224–e0259224. 1 indexed citations

Rao, Benchen, Daming Wang, Chunyu Zhao, et al.. (2025). Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study. BMC Infectious Diseases. 25(1). 275–275.

Sun, Junyi, Di Zhu, Ling Wang, et al.. (2025). Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19. Scientific Reports. 15(1). 11022–11022. 1 indexed citations

Liu, Zhihan, et al.. (2025). Mechanistic insights into post-translational modifications in hepatic fibrosis: pathogenic roles and therapeutic potentials. Journal of Translational Medicine. 23(1). 1036–1036.

Zhang, Kai, et al.. (2024). Unveiling microbial dynamics in lung adenocarcinoma and adjacent nontumor tissues: insights from nicotine exposure and diverse clinical stages via nanopore sequencing technology. Frontiers in Cellular and Infection Microbiology. 14. 1397989–1397989. 6 indexed citations

Xu, Jianming, Yanqiao Zhang, Gang Wang, et al.. (2024). SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 4092–4092. 8 indexed citations

Liu, Ying, Huifen Wang, Yaoguang Li, & Zujiang Yu. (2023). Clinical application of metagenomic next-generation sequencing in tuberculosis diagnosis. Frontiers in Cellular and Infection Microbiology. 12. 984753–984753. 23 indexed citations

Li, Ang, Gabriel Vinderola, Akihito Endo, et al.. (2022). Gut Microbiome Characteristics in feral and domesticated horses from different geographic locations. Communications Biology. 5(1). 172–172. 24 indexed citations

10.

Yu, Zujiang, et al.. (2021). Disturbance of hepatocyte growth and metabolism in a hyperammonemia microenvironment. Archives of Biochemistry and Biophysics. 716. 109109–109109. 4 indexed citations

11.

Bai, Lu, et al.. (2020). Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. Journal of Cellular Biochemistry. 122(9). 983–992. 6 indexed citations

12.

Rao, Benchen, Jiamin Lou, Weijie Wang, et al.. (2020). Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international. 19(2). 109–115. 26 indexed citations

13.

Shen, Shen, Dylan C. Dean, Zujiang Yu, & Zhenfeng Duan. (2019). Role of cyclin‐dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. Hepatology Research. 49(10). 1097–1108. 40 indexed citations

14.

Ren, Zhigang, Xinmei Chen, Liangjie Hong, et al.. (2019). Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis. Small. 16(2). e1905233–e1905233. 100 indexed citations

15.

Chang, Xiujuan, Yan Chen, Zujiang Yu, et al.. (2019). On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World Journal of Gastroenterology. 25(32). 4764–4778. 16 indexed citations

16.

Xu, Xiaopei, et al.. (2019). Long intergenic noncoding RNA SNHG16 interacts with miR-195 to promote proliferation, invasion and tumorigenesis in hepatocellular carcinoma. Experimental Cell Research. 383(1). 111501–111501. 31 indexed citations

17.

Ren, Zhigang, Ang Li, Jianwen Jiang, et al.. (2018). Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 68(6). 1014–1023. 543 indexed citations breakdown →

18.

Zhou, Yubing, Jacson Shen, Zujiang Yu, et al.. (2018). Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(5). 1573–1582. 54 indexed citations

19.

Pan, Yanfeng, Tao Qin, Lei Feng, & Zujiang Yu. (2013). Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma. Journal of Huazhong University of Science and Technology [Medical Sciences]. 33(1). 96–101. 33 indexed citations

20.

Xie, Wen, Guangfeng Shi, Hongfei Zhang, et al.. (2011). A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatology International. 6(2). 441–448. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact